The FDA has approved Lannett’s (NYSE:LCI) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company’s branded local anesthetic product.
Product launch is expected shortly under the brand name NUMBRINO.
NUMBRINO is indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.
Shares are up 15% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.